



Role of Microbiology in Tackling Antimicrobial Resistance: Implications for Food Safety and Public Health

Jahangir Khan¹, Sadaqat Ali², Muhammad Usman³, Haseeb Asif⁴, Maqsood Ahmad⁵, Syeda Fakhra Waheed⁶, Umber Rauf⁷, Muhammad Ali⁸, Sadia Arif⁹, Arish Hayat¹⁰

¹Primary and Secondary Health Care, The Islamia University of Bahawalpur, Punjab, Pakistan.

²College of Food Science and Engineering, Guangdong Ocean University, China.

³Department of Poultry Science, University of Agriculture, Faisalabad, Constituent College, Toba Tek Singh, Punjab, Pakistan.

⁴Department of Pathobiology, Section of Microbiology, University of Veterinary and Animal Sciences, Lahore, Sub Campus Jhang, Punjab, Pakistan.

⁵Livestock and Dairy Development Department, Directorate of Animal Disease Diagnostic, Reporting and Surveillance, Lahore, Punjab, Pakistan.

⁶Department of Veterinary Sciences, Faculty of Veterinary and Animal Sciences, Azad Jammu and Kashmir University of Bhimber-Bhimber AJK, Pakistan.

⁷Veterinary Research Institute, Zarar Shaheed Road Lahore Cantt, Punjab, Pakistan.

⁸Department of Pathobiology, Faculty of Veterinary and Animal Sciences, University of Layyah, Layyah, Punjab, Pakistan.

⁹Department of Biological Sciences, The Superior University, Lahore, Punjab, Pakistan.

¹⁰Department of Food Science and Technology, Bahauddin Zakaria University, Multan, Punjab, Pakistan.

ARTICLE INFO

Keywords

Antimicrobial Resistance, Microbiology, One Health, Foodborne Pathogens, Antimicrobial Stewardship, Environmental Resistance, Alternative Therapies.

Corresponding Author: Muhammad Usman, Department of Poultry Science, University of Agriculture, Faisalabad, Constituent College, Toba Tek Singh, Punjab, Pakistan.

Email: muhammadusman@uaf.edu.pk

Declaration

Author's Contributions: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History

Received: 22-10-2024

Revised: 20-12-2024

Accepted: 05-01-2025

ABSTRACT

Antimicrobial resistance (AMR) represents a burgeoning worldwide health hazard with profound consequences for public health, food safety, and the efficacy of contemporary treatment. This review examines the significance of microbiology in comprehending, identifying, and addressing antimicrobial resistance (AMR), emphasizing its effects on the food supply and public health. The main aim of this review is to consolidate existing research on the microbiological mechanisms underlying antimicrobial resistance (AMR), encompassing genetic mutations, horizontal gene transfer, and biofilm formation, while also investigating the environmental and agricultural factors that intensify the dissemination of resistance. The review thoroughly examines the literature, highlighting significant information gaps, especially regarding the dissemination of AMR across ecosystems and the microbiome's role in resistance. Significant findings underscore the relevance of the One Health paradigm in connecting human, animal, and environmental health, together with the encouraging progress in diagnostic tools and alternative treatments, like bacteriophage therapy. The review highlights the increasing worry regarding antimicrobial-resistant foodborne microorganisms, stressing the necessity for enhanced surveillance and more stringent agricultural controls. The review addresses the constraints of existing research, notably the absence of long-term studies evaluating the efficacy of antimicrobial stewardship programs and the insufficient comprehension of environmental reservoirs of resistance. The review ultimately offers recommendations for future research, advocating for integrated studies that monitor resistance across human, animal, and environmental sectors and more excellent investigation of innovative therapy strategies. The paper comprehensively analyzes the problems and opportunities in addressing AMR. It offers significant insights for formulating effective strategies to battle this vital worldwide issue.

INTRODUCTION

Antimicrobial resistance (AMR) has emerged as a significant worldwide health concern with serious ramifications for public health, food safety, and the management of infectious diseases. The introduction and proliferation of resistant microorganisms jeopardize decades of medical advancements, rendering previously

curable illnesses progressively challenging to manage (Dadgostar, 2019). Antimicrobial resistance (AMR) arises when microorganisms, including bacteria, fungi, and viruses, develop ways to withstand the effects of pharmacological agents intended to eradicate or suppress their proliferation. AMR is acknowledged as an



escalating issue in clinical environments, with its effects extending widely, as transmission occurs among human and animal populations, in addition to environmental reservoirs (Bennani et al., 2020). This issue impacts human health, agriculture, veterinary medicine, and the global food supply system. This review consolidates existing material to elucidate the function of microbiology in addressing antimicrobial resistance (AMR), emphasizing its significance for food safety and public health (Collineau et al., 2019).

Recent investigations have underscored substantial advancements in comprehending the mechanisms underlying antimicrobial resistance (AMR), encompassing genetic mutations, horizontal gene transfer, and the microbiome's function in disseminating resistance (Anthony et al., 2021). Nonetheless, a significant gap persists in comprehending the dissemination of resistant bacteria throughout ecosystems, primarily via the food chain, and the role of environmental factors in resistance development (Wang et al., 2021). Although extensive studies have been undertaken on the clinical dimensions of AMR, knowledge concerning the broader environmental and agricultural variables that intensify the issue remains inadequate (Wang et al., 2021). Research indicates that excessive antibiotic usage in agriculture hastens resistance in foodborne bacteria; nonetheless, the comprehensive understanding of this transmission mechanism and its public health implications remains insufficient (Roth et al., 2019). Rectifying these deficiencies is crucial for formulating successful methods to prevent antimicrobial resistance and maintaining the efficacy of medications (Chieffi et al., 2023).

This study aims to bridge knowledge gaps by examining the microbiological mechanisms that contribute to antimicrobial resistance (AMR), emphasizing the interrelation of human, animal, and environmental health (Kiambi et al., 2021). This review synthesizes existing research on microbiology's involvement in detecting, monitoring, and regulating antimicrobial resistance (AMR) to offer new insights into preventing and treating resistant infections (Miranda et al., 2021). This methodology addresses prior research deficiencies that frequently emphasize singular facets of antimicrobial resistance, such as clinical or agricultural investigations, while neglecting the broader ecological and public health ramifications (Kim & Koo, 2020). The review seeks to enhance the development of comprehensive strategies to address antimicrobial resistance (AMR) by incorporating microbiological, environmental, and policy perspectives, thereby guiding future research and influencing public health policies (Kim & Koo, 2020).

Background and Context

Overview of Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) is when microorganisms, including bacteria, fungi, viruses, and parasites, develop resistance to medications that previously eliminated or suppressed their proliferation (Zingg, Storr, et al., 2019). This resistance renders conventional therapies ineffective, resulting in extended sickness, elevated mortality rates, and more significant healthcare expenditures (Nejjari et al., 2022). Antimicrobial resistance (AMR) constitutes a significant global health challenge, jeopardizing decades of advancements in treating infectious diseases (Sukri et al., 2021). The World Health Organization (WHO) has persistently identified antimicrobial resistance (AMR) as a public health priority, cautioning that, without immediate intervention, it may lead to millions of fatalities each year and the disintegration of contemporary healthcare systems (Cerini et al., 2023).

Multiple causes, such as the excessive and improper utilization of antibiotics in human and veterinary medicine, inadequate infection control measures, and the scarcity of novel antibiotics under development, propel the emergence of antimicrobial resistance (AMR) (Rajendran et al., 2020). Antimicrobial resistance (AMR) also develops organically as bacteria adjust to endure selection pressure from antimicrobial agents. Nevertheless, human actions, especially the improper utilization of antibiotics, expedite this process (Day et al., 2022). For instance, the unwarranted prescription of antibiotics for viral infections or patients' failure to finish their treatment regimen allows resistant strains to flourish and disseminate (Neill et al., 2020). A significant issue regarding AMR is that treatable infections may develop and become treatment-resistant every day. Bacterial infections such as pneumonia, TB, and urinary tract infections may become resistant to conventional antibiotics, heightening the risk of complications and mortality (Vijay et al., 2021). In critical instances, infections from resistant bacteria might pose a life-threatening risk, even to those who were previously healthy (MARÇAL & BERTOLLO, 2020).

The Role of Microbiology in AMR Understanding


Microbiology is essential for comprehending and addressing antimicrobial resistance (AMR), as it establishes the basis for examining pathogen biology and the mechanisms of resistance development as shown in Figure 1. Microbiologists investigate how microbes circumvent antimicrobial drugs, essential for developing novel therapies and tactics to combat resistance (Saha & Mukherjee, 2019). A primary mechanism of antimicrobial resistance (AMR) is genetic mutation.

Microorganisms can develop resistance through mutations in their genetic material, allowing them to endure exposure to antimicrobial treatments (Lerminiaux & Cameron, 2019). Mutations may arise spontaneously; nevertheless, increased exposure of microorganisms to antibiotics provides more significant potential for developing resistance. Bacteria can mutate to prevent antibiotic entry through their cell walls or develop enzymes that degrade the antibiotic before its efficacy. Alongside genetic changes, horizontal gene transfer (HGT) is a significant route for disseminating resistance. Horizontal gene transfer (HGT) transpires when one bacterium conveys genetic material, encompassing genes responsible for antibiotic resistance, to another bacterium. The transfer may occur via conjugation, transformation, and transduction, facilitating the fast dissemination of resistance among bacterial populations, including between distinct species (Lerminiaux & Cameron, 2019).

Biofilm development is a significant component contributing to antimicrobial resistance (AMR). A multitude of bacteria can generate biofilms, which are aggregates of microorganisms encased in a protective matrix of extracellular materials (Pacífico et al., 2019). Biofilms significantly impede the penetration of antibiotics, rendering the bacteria within them more resistant than their free-living counterparts. Biofilms may develop on medical devices, including catheters, prosthetics, and ventilators, complicating infection treatment and elevating the risk of persistent infections (Moye et al., 2020). Microbiologists examine the interplay between pathogens and host organisms. Resistance may develop due to the host's immunological response or antimicrobial therapies. Pathogens may evolve strategies to circumvent immune recognition, complicating the resolution of infections. Comprehending these relationships facilitates the advancement of superior vaccinations, diagnostics, and therapeutic techniques (Blasco et al., 2020).

Furthermore, microbiology aids in advancing alternative therapeutics to address antimicrobial resistance (AMR). A possible approach is the utilization of bacteriophages, viruses that mainly infect and eradicate bacteria. This method presents a viable remedy for addressing infections induced by resistant bacteria (Sridharan et al., 2021). Moreover, microbiologists are investigating the function of the microbiome, the vast array of bacteria residing in and on the human body, in antimicrobial resistance (AMR). Investigating the microbiome's impact on resistance may yield innovative therapies, including applying probiotics to reestablish a healthy microbial equilibrium and inhibit the proliferation of resistant bacteria (Schuch et al., 2019).

Figure 1



This flowchart illustrates the pivotal role of microbiology in understanding and combating antimicrobial resistance (AMR). It outlines the key processes involved in microbial analysis, including identification and susceptibility testing, and details the resistance mechanisms such as mutations, horizontal gene transfer, and biofilm formation. The flowchart further highlights the impact of AMR on public health, including increased morbidity, mortality, and limited treatment options, as well as its effects on food safety, mainly through contamination and the transfer of resistant strains from animals to humans. Ultimately, it emphasizes the critical contributions of microbiology in detecting, monitoring, and addressing AMR through improved diagnostics, novel treatments, and better surveillance systems.

Microbiological Approaches to Combat AMR

Microbial Surveillance and Resistance Monitoring

Surveillance is a crucial microbiological strategy for addressing antimicrobial resistance (AMR). Ongoing surveillance of resistance patterns facilitates the assessment of the presence and dissemination of resistant infections, directing public health initiatives and shaping treatment approaches. Surveillance systems are crucial for detecting new resistant strains and monitoring trends across time, facilitating prompt responses to future AMR problems (Mo et al., 2023). Diverse methodologies are employed for surveillance, encompassing conventional microbiological culture techniques and more sophisticated molecular ones. Phenotypic techniques, like disk diffusion and broth dilution, directly assess bacterial susceptibility to various antibiotics (Turner et al., 2019). These technologies facilitate the identification of resistant infections in clinical environments and can be expanded for national or international surveillance systems (Müller-Schulte et al., 2020).

Genomic methodologies, including whole-genome sequencing (WGS), provide a more comprehensive and precise approach to monitoring antimicrobial resistance (AMR). Whole Genome Sequencing (WGS) can discover resistance genes and their genetic context, offering insights into the evolution and dissemination of

resistance. This data can facilitate the tracking of genetic lineages of resistant strains, the mapping of resistance hotspots, and the identification of epidemic sources (Li et al., 2021). Moreover, genetic surveillance enables real-time monitoring, allowing expedited responses to new risks. International entities, such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), are pivotal in orchestrating antimicrobial resistance (AMR) surveillance initiatives. They formulate protocols for resistance surveillance, disseminate data internationally, and advocate for optimal infection prevention and control practices (Mo et al., 2023). National surveillance initiatives, such as the European Antimicrobial Resistance Surveillance Network (EARS-Net) and the Global Antimicrobial Resistance Surveillance System (GLASS), facilitate the standardization of data collection and guarantee that global responses to antimicrobial resistance (AMR) are founded on dependable, uniform information (Maganga et al., 2023).

Microbiological Detection of Resistance in Clinical and Environmental Samples

Timely and precisely identifying antimicrobial resistance (AMR) is essential for effective treatment and infection management. Microbiological laboratories help identify resistant bacteria in clinical and environmental specimens. In clinical environments, microbiologists isolate and identify infections from patient specimens, subsequently conducting antimicrobial susceptibility testing to ascertain the pathogen's resistance to specific medications (Surányi et al., 2023). Conventional techniques, such as agar dilution and disk diffusion, remain the benchmark for identifying resistance; nevertheless, they are often time-consuming and labor-intensive (Weis et al., 2020). Accelerated techniques, such as PCR (polymerase chain reaction) testing, facilitate the identification of particular resistance genes within hours. PCR effectively identifies resistance to methicillin, vancomycin, and carbapenems, commonly linked to multidrug-resistant bacteria (Ouarti et al., 2020).

A notable tool for resistance detection is matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). This technique identifies bacterial species and discovers resistance indicators by analyzing the bulk of bacterial proteins, providing high throughput and swift results. MALDI-TOF MS can be included in clinical microbiology processes to enhance resistance monitoring (Guindo et al., 2022). Environmental microbiology is essential for the detection of antimicrobial resistance (AMR). Monitoring water, soil, and food sources for resistant bacteria aids in comprehending the propagation of resistance in natural ecosystems (Urakami & Hinou, 2024). Antimicrobial resistance (AMR) in the environment is an escalating issue attributed to the

pervasive contamination of ecosystems by pharmaceutical residues, agricultural runoff, and untreated sewage. Surveillance of environmental samples is crucial for comprehending AMR's extensive effects and averting additional transmission to human populations (Samaranayake et al., 2020).

Development of New Antimicrobial Agents

The advancement of novel antimicrobial agents is crucial for addressing the shortcomings of current therapies, particularly as resistance to conventional medications escalates. Microbiologists are at the forefront of discovering and developing new antibiotics and alternative medicines (McCallin et al., 2019). Pharmaceutical firms have markedly diminished their investment in antibiotic research in recent decades. However, novel methodologies for drug development are being investigated (Kornienko et al., 2020). Screening natural products has resulted in the discovery of potential novel antibiotics. Soil bacteria, fungi, and marine organisms are recognized for producing diverse antimicrobial chemicals, many of which may act as templates for novel medication development. Researchers are investigating synthetic biology and chemical engineering methods to develop novel compounds exhibiting antibacterial characteristics (McCallin et al., 2019).

Bacteriophages, viruses that selectively infect and eradicate bacteria, are undergoing reevaluation as a prospective therapy for drug-resistant diseases. Phage therapy, previously utilized in the early 20th century before the introduction of antibiotics, is experiencing a resurgence as an alternative to conventional antibiotics (Lebeaux et al., 2021). Phages can be customized to target resistant bacteria, rendering them a compelling choice for precision therapy. Alongside the discovery of novel antibiotics, microbiologists are investigating methods to counteract resistance by obstructing the mechanisms employed by bacteria to evade medications. For instance, beta-lactamase enzyme inhibitors, which degrade medicines such as penicillin, are being engineered to reinstate the effectiveness of older antibiotics (Sisakhtpour et al., 2022).

Microbiome Research and AMR

The human microbiome, comprising billions of bacteria residing in and on our bodies, is integral to developing and disseminating antimicrobial resistance (AMR). Microbiome research provides insights into how the equilibrium of microbial populations influences resistance patterns. Disruptions to the microbiome, such as those induced by antibiotic use, can facilitate the proliferation of resistant bacteria, resulting in infections that are challenging to manage (Msolo et al., 2020). Researchers are exploring methods to modify the microbiome to address antimicrobial resistance (AMR). Probiotics, prebiotics, and fecal microbiota

transplantation (FMT) are viable methods for reestablishing a healthy microbial equilibrium and inhibiting the proliferation of resistant infections. These therapies are now employed to address *Clostridium difficile* infections and are under investigation for their potential to avoid additional forms of antimicrobial resistance (AMR) (Afshar et al., 2023). Microbiologists are investigating the relationships of human, animal, and environmental microbiomes to comprehend the dissemination of resistance throughout many habitats. The One Health concept acknowledges the interrelation of human, animal, and environmental health, highlighting the necessity for cohesive microbiological surveillance and intervention to address antimicrobial resistance globally (Otto et al., 2022).

Antimicrobial Resistance in the Food Chain

Transmission of AMR from Animals to Humans

A significant concern regarding antimicrobial resistance (AMR) is the possibility of resistance being passed from animals to humans. Antimicrobial-resistant bacteria can disseminate through ingesting tainted meat, milk, eggs, and other animal-derived items within the food chain (Caballero Gómez et al., 2022). This establishes a direct connection between veterinary medicine and public health, as animals administered antibiotics may have resistant strains that can infect humans through the food chain. Furthermore, resistant infections may be disseminated via handling, processing, and environmental factors, including contaminated water or soil utilized in agriculture (Ježak & Kozajda, 2022).

Common foodborne bacteria such as *Salmonella*, *Escherichia coli*, and *Campylobacter* can acquire antibiotic resistance when subjected to antibiotics utilized in animal agriculture. These bacteria can then be passed to people, leading to illnesses that are more challenging to cure with standard medications (Ogunshe). The worldwide increase of resistant *Salmonella* strains, especially those resistant to fluoroquinolones and extended-spectrum beta-lactams, constitutes a significant public health concern. The transmission of antimicrobial resistance (AMR) from animals to people occurs not just via food intake but also through direct contact with animals, especially during slaughtering and handling, or from agricultural workers exposed to antibiotic-resistant bacteria (Abdalla et al., 2021).

Role of Agriculture and Veterinary Medicine in AMR

Antibiotics are extensively used in agriculture and veterinary care to treat ill animals and as a prophylactic step to enhance growth in healthy animals. The excessive and improper use of antibiotics in cattle and poultry husbandry has contributed significantly to the emergence of antimicrobial resistance (AMR) (Mshana et al., 2021). The administration of antibiotics in healthy

animals, particularly as growth enhancers, fosters an environment conducive to the proliferation of resistant bacteria, resulting in resistant strains that may be transmitted to people (Fang et al., 2021).

Various countries have implemented regulatory measures to govern antibiotic usage in agriculture to mitigate antimicrobial resistance (AMR). Since 2006, the European Union has prohibited the use of antibiotics as growth promoters, whilst the U.S. Food and Drug Administration (FDA) has established guidelines to restrict the use of medically significant antibiotics in food animals (Matin et al., 2020). Notwithstanding these initiatives, apprehensions persist regarding the ongoing utilization of antibiotics in food production, especially in nations with lax laws. Antimicrobial resistance in agriculture impacts both human health and economic stability. The emergence of antibiotic-resistant bacteria in animals can result in diminished output, extended treatment durations, and increased veterinary expenses, complicating the maintenance of healthy livestock herds (Da Silva et al., 2023).

Implications for Public Health

Impact of AMR on Public Health

Antimicrobial resistance (AMR) constitutes a significant global public health threat by diminishing the efficacy of widely utilized antibiotics and other antimicrobial treatments. Resistant infections result in prolonged hospitalizations, increased need for intensive care, and elevated fatality rates. Infections that were previously manageable with medications have suddenly become challenging or even unmanageable. This considerably strains global healthcare systems, as the expenses associated with managing resistant diseases are markedly more than those for non-resistant infections (Herrera-Espejo et al., 2022). The ramifications of antimicrobial resistance (AMR) encompass a broad spectrum of disorders, including prevalent infections such as urinary tract infections (UTIs) and pneumonia, as well as more intricate ailments like tuberculosis (TB), HIV, and sepsis (Che et al., 2019). Resistant bacterial strains such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus aureus* are progressively accountable for hospital-acquired infections, many of which correlate with elevated mortality rates owing to restricted therapy alternatives (Tuat et al., 2021).

Carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant *Mycobacterium tuberculosis* are increasingly considered significant public health hazards. The rise of resistance to last-resort antibiotics such as carbapenems and colistin constitutes a critical issue, especially in low-income and middle-income nations, where access to novel medications and sophisticated medical treatment is restricted (Herrera-Espejo et al., 2022). Furthermore, AMR jeopardizes the efficacy of contemporary medicinal interventions.

Surgical procedures, oncological therapies, and organ transplantation significantly depend on efficient antibacterial prophylaxis to avert infections. If antibiotics lose their efficacy, these treatments would entail significantly more significant risks of infection and consequences, rendering them potentially life-threatening (Foxlee et al., 2023).

Public Health Strategies to Combat AMR

Many public health interventions are being executed at national, regional, and global scales in response to the escalating AMR epidemic. A primary strategy is enhancing antimicrobial stewardship and optimizing antibiotic utilization in human healthcare and agriculture. This entails guaranteeing that antibiotics are provided solely when warranted, at the appropriate dosages, and for the correct period. In hospitals, antimicrobial stewardship initiatives aim to minimize incorrect prescriptions, curtail overuse, and utilize narrow-spectrum antibiotics whenever feasible (Lee & Bradley, 2023). Moreover, surveillance systems are crucial in monitoring the dissemination of antimicrobial resistance (AMR), facilitating the early identification of resistant strains, and guiding control strategies. Public health organizations, like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), have created national and worldwide monitoring systems to track the frequency of resistant diseases (Al-Omari et al., 2020).

Mitigating the dissemination of antimicrobial resistance necessitates enhanced infection prevention and control protocols, including hand cleanliness, safe surgical techniques, and using personal protective equipment (PPE) in medical environments. Vaccination is essential, as it diminishes the need for medicines by initially averting illnesses. Vaccines for pneumococcal disease, influenza, and several bacterial infections might diminish the occurrence of illnesses that may otherwise necessitate antibiotic intervention (Daniels & Weber, 2021). Public awareness efforts are essential for promoting safe antibiotic usage and preventing self-medication, which may lead to resistance. Informing the public about the risks associated with the excessive use of antibiotics, particularly for viral illnesses, is an essential component of any national strategy to address antimicrobial resistance (AMR) (Ticcioni et al., 2021).

Challenges

Challenges in Tackling AMR

The struggle against antimicrobial resistance (AMR) is filled with several problems that hinder worldwide initiatives to alleviate its effects as shown in Figure 2. The overuse and misuse of antibiotics in human and animal populations constitute a significant challenge. Antibiotics are frequently misused for viral diseases, when they are ineffective, or when a bacterial infection is suspected but not verified (Ukuhor, 2021). In certain

instances, individuals do not finish their prescribed antibiotic regimens, enabling remaining germs to adapt and acquire resistance. The indiscriminate application of antibiotics in agriculture to enhance growth in healthy cattle has contributed to the establishment of resistant strains (Christensen, 2021).


Notwithstanding increasing awareness, the prevalent misuse of antibiotics continues to be a persistent problem. A significant concern is the scarcity of novel antibiotics. The advancement of novel antimicrobial medicines has markedly decelerated in recent decades as pharmaceutical corporations exhibit growing hesitance to invest in antibiotic research (Yang et al., 2019). The development of new antibiotics is expensive, and the protracted deadlines for regulatory approval and restricted financial returns have prompted numerous corporations to concentrate on more lucrative therapeutic domains. As a result, the pipeline for novel antibiotics is insufficient, resulting in diminished treatment alternatives as resistance proliferates (Yalew, 2020).

Economic and logistical limitations in wealthy and developing nations impede initiatives to address AMR. Numerous low- and middle-income nations face challenges establishing sufficient healthcare infrastructure, encompassing the necessary resources for monitoring antimicrobial resistance (AMR), executing infection control protocols, and performing resistance surveillance (Christensen, 2021). These nations may encounter challenges in obtaining high-quality medications, intensifying the issues of self-medication and antibiotic overuse. In industrialized nations, the emphasis on costly and sophisticated medicines frequently neglects more holistic approaches designed to avoid the initial development of resistance (Dutescu & Hillier, 2021).

The global inconsistency in rules and enforcement exacerbates the challenge of combating AMR. Some countries possess stringent rules regarding antibiotic usage in human health and agriculture, whereas others exhibit lenient laws or inadequate enforcement (Ali et al., 2022). This discrepancy engenders deficiencies in global control mechanisms, facilitating the transnational proliferation of resistant microorganisms. The global movement of individuals, animals, and commodities promotes the dissemination of resistant infections, rendering antimicrobial resistance a genuinely transnational concern necessitating synchronized global efforts. The insufficient public awareness of the perils of AMR constitutes a considerable challenge. Although healthcare experts are becoming more cognizant of the issue, the general populace frequently lacks understanding regarding the appropriate usage of antibiotics. This misinformation, combined with the propensity to self-medicate or request antibiotics for

non-indicated diseases, intensifies the issue of misuse (Le et al., 2023).

Figure 2



This diagram illustrates the various challenges in addressing antimicrobial resistance (AMR), highlighting key factors such as the overuse and misuse of antibiotics in human and animal populations, the slow development of new antibiotics, and the economic and logistical limitations faced by both wealthy and developing nations. It also emphasizes global inconsistencies in regulations, insufficient public awareness, and the challenges posed by the movement of people, animals, and goods, which facilitate the spread of resistant infections. These interconnected issues underscore the complexity of tackling AMR and the need for coordinated global efforts to mitigate its impact on public health and food safety.

Future Directions

As antimicrobial resistance (AMR) persists as a global issue, innovative technologies offer significant potential to tackle the challenges of resistance detection, treatment, and prevention. A significant advancement in AMR research is the application of next-generation sequencing (NGS). Next-generation sequencing technologies facilitate high-throughput, extensive genomic investigation of infections, allowing researchers to detect resistance genes and trace their dissemination more effectively than conventional methods (Zingg, Park, et al., 2019). Through the sequencing of the complete genome of resistant bacteria, NGS aids in detecting established resistance markers while also revealing new resistance mechanisms, hence enabling the swift identification of emergent resistance threats. The amalgamation of genomic data with clinical results can facilitate individualized treatment options that are more efficacious in addressing resistant illnesses (Diep et al., 2022).

Artificial intelligence (AI) and machine learning are crucial in combating antimicrobial resistance (AMR). Artificial intelligence can forecast resistance trends, simulate the dissemination of resistant microorganisms, and enhance antibiotic utilization. Machine learning

algorithms, trained on vast microbiological and clinical data datasets, can help identify early warning signs of AMR outbreaks, predict the future evolution of resistance, and support the development of new drugs by analyzing molecular structures (Bapat & Nobile, 2021). Moreover, AI-powered diagnostic tools, such as rapid diagnostic kits that utilize machine learning algorithms, can provide real-time information on the resistance profiles of bacterial infections, enabling healthcare providers to make informed decisions on treatment options (Magnano San Lio et al., 2023).

CRISPR-based technologies are potentially transformative for addressing antimicrobial resistance (AMR). CRISPR gene-editing methods can directly target and deactivate resistance genes in bacteria. Researchers are investigating methods to utilize CRISPR systems to eradicate resistance genes from bacterial populations or augment the susceptibility of resistant bacteria to current antibiotics (Bassetti et al., 2020). This precise methodology could significantly transform AMR treatment by reinstating the efficacy of antiquated medicines or making resistant organisms more susceptible to contemporary medications (Kiga et al., 2020).

CONCLUSION

This review underscores the pressing and complex issue of antimicrobial resistance (AMR), highlighting the essential role of microbiology in comprehending, identifying, and addressing this worldwide menace. Antimicrobial resistance (AMR), caused by the excessive and improper use of antibiotics in human healthcare and agriculture, has resulted in resistant microorganisms undermining existing treatments' efficacy. Critical findings from the review emphasize the significance of microbiological research in elucidating the mechanisms of resistance, encompassing genetic mutations, horizontal gene transfer, and biofilm formation. The incorporation of sophisticated technologies like next-generation sequencing and artificial intelligence provide effective instruments for the swift identification and forecasting of resistance patterns. Moreover, the One Health strategy, which integrates human, animal, and environmental health, is crucial for holistically addressing antimicrobial resistance (AMR). Despite considerable advancements, notable deficiencies persist, especially regarding the ecological dissemination of resistant bacteria and the sustained efficacy of antimicrobial stewardship initiatives. The sluggish advancement of new antibiotics underscores the necessity for ongoing investment in research and innovation, encompassing alternative medicines like bacteriophage therapy and CRISPR-based gene editing. The analysis highlighted discrepancies in worldwide AMR responses, emphasizing the necessity for enhanced international

cooperation and unified policy frameworks. Future studies should focus on environmental surveillance, comprehensive One Health investigations, and assessing novel therapeutic approaches. Notwithstanding the hurdles, the analysis closes with a hopeful perspective

that, through sustained interdisciplinary collaboration, technological innovation, and comprehensive public health measures, progress in combating AMR can be achieved, thereby preserving the efficacy of antibiotics for future generations.

REFERENCES

- Abdalla, S. E., Abia, A. L., Amoako, D. G., Perrett, K., Bester, L. A., & Essack, S. Y. (2021). From farm-to-Fork: E. Coli from an intensive pig production system in South Africa shows high resistance to critically important antibiotics for human and animal use. *Antibiotics*, 10(2), 178. <https://doi.org/10.3390/antibiotics10020178>
- Afshar, M. F., Zakaria, Z., Cheng, C. H., & Ahmad, N. I. (2023). Prevalence and multidrug-resistant profile of methicillin-resistant staphylococcus aureus and methicillin-resistant staphylococcus pseudintermedius in dogs, cats, and pet owners in Malaysia. *Veterinary World*, 536-545. <https://doi.org/10.14202/10.14202/vetworld.2023.536-545>
- Ali, A. R., Bahrami, Y., Kakaei, E., Mohammadzadeh, S., Bouk, S., & Jalilian, N. (2022). Isolation and identification of endophytic actinobacteria from Citrullus colocynthis (L.) Schrad and their antibacterial properties. *Microbial Cell Factories*, 21(1). <https://doi.org/10.1186/s12934-022-01936-9>
- Al-Omari, A., Al Mutair, A., Alhumaid, S., Salih, S., Alanazi, A., Albarsan, H., Abourayan, M., & Al Subaie, M. (2020). The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: Results of a five-years pre-post analysis. *Antimicrobial Resistance & Infection Control*, 9(1). <https://doi.org/10.1186/s13756-020-00751-4>
- Anthony, W. E., Burnham, C. D., Dantas, G., & Kwon, J. H. (2020). The gut microbiome as a reservoir for antimicrobial resistance. *The Journal of Infectious Diseases*, 223(Supplement_3), S209-S213. <https://doi.org/10.1093/infdis/jiaa497>
- Bapat, P. S., & Nobile, C. J. (2021). Photodynamic therapy is effective against candida auris Biofilms. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.713092>
- Bassetti, M., Rello, J., Blasi, F., Goossens, H., Sotgiu, G., Tavošchi, L., Zasowski, E. J., Arber, M. R., McCool, R., Patterson, J. V., Longshaw, C. M., Lopes, S., Manissero, D., Nguyen, S. T., Tone, K., & Aliberti, S. (2020). Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. *International Journal of Antimicrobial Agents*, 56(6), 106184. <https://doi.org/10.1016/j.ijantimicag.2020.106184>
- Bennani, H., Mateus, A., Mays, N., Eastmure, E., Stärk, K. D., & Häslér, B. (2020). Overview of evidence of antimicrobial use and antimicrobial resistance in the food chain. *Antibiotics*, 9(2), 49. <https://doi.org/10.3390/antibiotics9020049>
- Blasco, L., Ambroa, A., Trastoy, R., Blieriot, I., Moscoso, M., Fernández-García, L., Perez-Nadales, E., Fernández-Cuenca, F., Torre-Cisneros, J., Oteo-Iglesias, J., Oliver, A., Canton, R., Kidd, T., Navarro, F., Miró, E., Pascual, A., Bou, G., Martínez-Martínez, L., & Tomas, M. (2020). In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. *Scientific Reports*, 10(1). <https://doi.org/10.1038/s41598-020-64145-7>
- Caballero Gómez, N., Manetsberger, J., Benomar, N., Castillo Gutiérrez, S., & Abriouel, H. (2022). Antibacterial and antibiofilm effects of essential oil components, EDTA and HLE disinfectant solution on Enterococcus, pseudomonas and staphylococcus Sp. multiresistant strains isolated along the meat production chain. *Frontiers in Microbiology*, 13. <https://doi.org/10.3389/fmicb.2022.1014169>
- Cerini, P., Meduri, F. R., Tomassetti, F., Polidori, I., Brugnati, M., Nicolai, E., Bernardini, S., Pieri, M., & Broccolo, F. (2023). Trends in antibiotic resistance of nosocomial and community-acquired infections in Italy. *Antibiotics*, 12(4), 651. <https://doi.org/10.3390/antibiotics12040651>
- Che, Y., Xia, Y., Liu, L., Li, A., Yang, Y., & Zhang, T. (2019). Mobile antibiotic resistome in wastewater treatment plants revealed by Nanopore metagenomic

- sequencing. *Microbiome*, 7(1). <https://doi.org/10.1186/s40168-019-0663-0>
- Chieffi, D., Fanelli, F., & Fusco, V. (2023). Antimicrobial and biocide resistance in staphylococcus aureus: Genomic features, decontamination strategies, and the role of S. aureus complex-related species, with a focus on ready-to-eat food and food-contact surfaces. *Frontiers in Food Science and Technology*, 3. <https://doi.org/10.3389/frfst.2023.1165871>
- Christensen, S. B. (2021). Drugs that changed society: History and current status of the early antibiotics: Salvarsan, sulfonamides, and β -lactams. *Molecules*, 26(19), 6057. <https://doi.org/10.3390/molecules26196057>
- Collineau, L., Boerlin, P., Carson, C. A., Chapman, B., Fazil, A., Hetman, B., McEwen, S. A., Parmley, E. J., Reid-Smith, R. J., Taboada, E. N., & Smith, B. A. (2019). Integrating whole-genome sequencing data into quantitative risk assessment of foodborne antimicrobial resistance: A review of opportunities and challenges. *Frontiers in Microbiology*, 10. <https://doi.org/10.3389/fmicb.2019.01107>
- CRUZ, L. F., MARÇAL, A. G., REIS, A. M., & BERTOLLO, C. M. (2020). Antimicrobial therapy in older adults: Profile of use and evaluation of the quality of prescription. *Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde*, 11(1), 0367. <https://doi.org/10.30968/rbfhss.2020.111.0367>
- Da Silva, R. A., Arenas, N. E., Luiza, V. L., Bermudez, J. A., & Clarke, S. E. (2023). Regulations on the use of antibiotics in livestock production in South America: A comparative literature analysis. *Antibiotics*, 12(8), 1303. <https://doi.org/10.3390/antibiotics12081303>
- Dadgostar, P. (2019). Antimicrobial resistance: Implications and Costs. *Infection and Drug Resistance*, 12, 3903-3910. <https://doi.org/10.2147/idr.s234610>
- Daniels, L. M., & Weber, D. J. (2020). Interventions to improve antibiotic prescribing at hospital discharge: A systematic review. *Infection Control & Hospital Epidemiology*, 42(1), 96-99. <https://doi.org/10.1017/ice.2020.367>
- Day, M. J., Spiteri, G., Jacobsson, S., Woodford, N., Amato-Gauci, A. J., Cole, M. J., & Unemo, M. (2018). Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in *Neisseria gonorrhoeae* in 25 European countries, 2016. *BMC Infectious Diseases*, 18(1). <https://doi.org/10.1186/s12879-018-3528-4>
- Diep, T. T., Bizley, S., & Edwards, A. D. (2022). 3D-Printed dip slides miniaturize bacterial identification and antibiotic susceptibility tests allowing direct mastitis sample analysis. *Micromachines*, 13(6), 941. <https://doi.org/10.3390/mi13060941>
- Dutescu, I. A., & Hillier, S. A. (2021). Encouraging the development of new antibiotics: Are financial incentives the right way forward? A systematic review and case study. *Infection and Drug Resistance*, 14, 415-434. <https://doi.org/10.2147/idr.s287792>
- Fang, J., Gong, G., Yuan, J., & Sun, X. (2020). Antibiotic use in pig farming and its associated factors in L County in Yunnan, China. *Veterinary Medicine and Science*, 7(2), 440-454. <https://doi.org/10.1002/vms3.390>
- Foxlee, N. D., Taleo, S. A., Mathias, A., Townell, N., McIver, L., & Lau, C. L. (2023). The impact of COVID-19 on knowledge, beliefs, and practices of Ni-Vanuatu health workers regarding antibiotic prescribing and antibiotic resistance, 2018 and 2022: A mixed methods study. *Tropical Medicine and Infectious Disease*, 8(10), 477. <https://doi.org/10.3390/tropicalmed8100477>
- Guindo, C. O., Amir, L., Couderc, C., Drancourt, M., & Grine, G. (2022). Rapid identification of clinically interesting methanogens using an improved MALDI-TOF-MS assay. *Access Microbiology*, 4(7). <https://doi.org/10.1099/acmi.0.000372>
- Herrera-Espejo, S., Del Barrio-Tofiño, E., Cebrero-Canguero, T., López-Causapé, C., Álvarez-Marín, R., Cisneros, J. M., Pachón, J., Oliver, A., & Pachón-Ibáñez, M. E. (2022). Carbapenem combinations for infections caused by carbapenemase-producing pseudomonas aeruginosa: Experimental in vitro and in vivo analysis. *Antibiotics*, 11(9), 1212. <https://doi.org/10.3390/antibiotics11091212>
- Ježak, K., & Kozajda, A. (2021). Occurrence and spread of antibiotic-resistant bacteria on animal farms and in their vicinity in Poland and Ukraine—review. *Environmental Science and Pollution Research*, 29(7), 9533-9559. <https://doi.org/10.1007/s11356-021-17773-z>
- Kiambi, S., Mwanza, R., Sirma, A., Czerniak, C., Kimani, T., Kabali, E., Dorado-Garcia, A., Eckford, S., Price, C., Gikonyo, S.,

- Byarugaba, D. K., & Caudell, M. A. (2021). Understanding antimicrobial use contexts in the poultry sector: Challenges for small-scale layer farms in Kenya. *Antibiotics*, 10(2), 106. <https://doi.org/10.3390/antibiotics10020106>
- Kiga, K., Tan, X., Ibarra-Chávez, R., Watanabe, S., Aiba, Y., Sato'o, Y., Li, F., Sasahara, T., Cui, B., Kawauchi, M., Boonsiri, T., Thitiananpakorn, K., Taki, Y., Azam, A. H., Suzuki, M., Penadés, J. R., & Cui, L. (2020). Development of CRISPR-cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-020-16731-6>
- Kim, H. J., & Koo, M. (2020). Occurrence, antimicrobial resistance and molecular diversity of *Enterococcus faecium* in processed pork meat products in Korea. *Foods*, 9(9), 1283. <https://doi.org/10.3390/foods9091283>
- Kornienko, M., Kuptsov, N., Gorodnichev, R., Bespiatykh, D., Guliaev, A., Letarova, M., Kulikov, E., Veselovsky, V., Malakhova, M., Letarov, A., Ilina, E., & Shitikov, E. (2020). Contribution of Podoviridae and Myoviridae bacteriophages to the effectiveness of anti-staphylococcal therapeutic cocktails. *Scientific Reports*, 10(1). <https://doi.org/10.1038/s41598-020-75637-x>
- Le, H., Dé, E., Le Cerf, D., & Karakasyan, C. (2023). Using targeted nano-antibiotics to improve antibiotic efficacy against staphylococcus aureus infections. *Antibiotics*, 12(6), 1066. <https://doi.org/10.3390/antibiotics12061066>
- Lebeaux, D., Merabishvili, M., Caudron, E., Lannoy, D., Van Simaey, L., Duyvejonck, H., Guillemain, R., Thumerelle, C., Podglajen, I., Compain, F., Kassis, N., Mainardi, J., Wittmann, J., Rohde, C., Pirnay, J., Dufour, N., Vermeulen, S., Gansemans, Y., Van Nieuwerburgh, F., ... Vaneechoutte, M. (2021). A case of phage therapy against pandrug-resistant *Achromobacter xylosoxidans* in a 12-Year-Old lung-transplanted cystic fibrosis patient. *Viruses*, 13(1), 60. <https://doi.org/10.3390/v13010060>
- Lee, Y., & Bradley, N. (2023). Antimicrobial stewardship practices in a subset of community pharmacies across the United States. *Pharmacy*, 11(1), 26. <https://doi.org/10.3390/pharmacy11010026>
- Lerminiaux, N. A., & Cameron, A. D. (2019). Horizontal transfer of antibiotic resistance genes in clinical environments. *Canadian Journal of Microbiology*, 65(1), 34-44. <https://doi.org/10.1139/cjm-2018-0275>
- Li, Z., Shi, R., Wu, H., & Yan, P. (2021). First identification of a patient with prosthesis-related infection caused by an MCR-1.1-Producing ST131 *Escherichia coli* after rhinoplasty. *Infection and Drug Resistance*, 14, 249-257. <https://doi.org/10.2147/idr.s295801>
- Maganga, R., Sindiyo, E., Musyoki, V. M., Shirima, G., & Mmbaga, B. T. (2023). Comparative analysis of clinical breakpoints, normalized resistance interpretation and epidemiological cut-offs in interpreting antimicrobial resistance of *Escherichia coli* isolates originating from poultry in different farm types in Tanzania. *Access Microbiology*, 5(7). <https://doi.org/10.1099/acmi.0.000540.v4>
- Magnano San Lio, R., Barchitta, M., Maugeri, A., La Rosa, M. C., Favara, G., & Agodi, A. (2023). Updates on developing and applying biosensors for the detection of microorganisms, antimicrobial resistance genes and antibiotics: A scoping review. *Frontiers in Public Health*, 11. <https://doi.org/10.3389/fpubh.2023.1240584>
- Matin, M. A., Khan, W. A., Karim, M. M., Ahmed, S., John-Langba, J., Sankoh, O. A., Gyapong, M., Kinsman, J., & Wertheim, H. (2020). What influences antibiotic sales in rural Bangladesh? A drug dispensers' perspective. *Journal of Pharmaceutical Policy and Practice*, 13(1). <https://doi.org/10.1186/s40545-020-00212-8>
- McCallin, S., Sacher, J. C., Zheng, J., & Chan, B. K. (2019). Current state of compassionate phage therapy. *Viruses*, 11(4), 343. <https://doi.org/10.3390/v11040343>
- Miranda, C., Contente, D., Igrejas, G., Câmara, S. P., Dapkevicius, M. D., & Poeta, P. (2021). Role of exposure to lactic acid bacteria from foods of animal origin in human health. *Foods*, 10(9), 2092. <https://doi.org/10.3390/foods10092092>
- Mo, Y., Ding, Y., Cao, Y., Hopkins, J., Ashley, E. A., Waithira, N., Wannapinij, P., Lee, S. J., Paterson, D. L., Doorn, H. R., & Turner, P. (2023). ACORN (A clinically-oriented antimicrobial resistance surveillance network) II: Protocol for case based antimicrobial resistance surveillance. *Wellcome Open Research*, 8, 179. <https://doi.org/10.12688/wellcomeopenres.19210.1>
- Moye, Z. D., Das, C. R., Tokman, J. I., Fanelli, B., Karathia, H., Hasan, N. A., Marek, P. J., Senecal, A. G., & Sulakvelidze, A. (2020). Treatment of fresh produce with a *Salmonella*

- targeted bacteriophage cocktail is compatible with chlorine or peracetic acid and more consistently preserves the microbial community on produce. *Journal of Food Safety*, 40(2). <https://doi.org/10.1111/jfs.12763>
- Mshana, S. E., Sindato, C., Matee, M. I., & Mboera, L. E. (2021). Antimicrobial use and resistance in agriculture and food production systems in Africa: A systematic review. *Antibiotics*, 10(8), 976. <https://doi.org/10.3390/antibiotics10080976>
- Msolo, L., Iweriebor, B. C., & Okoh, A. I. (2020). Antimicrobial resistance profiles of Diarrheagenic *E. coli* (DEC) and *Salmonella* species recovered from diarrheal patients in selected rural communities of the Amathole district municipality, Eastern Cape province, South Africa. *Infection and Drug Resistance*, 13, 4615-4626. <https://doi.org/10.2147/idr.s269219>
- Müller-Schulte, E., Tuo, M. N., Akoua-Koffi, C., Schaumburg, F., & Becker, S. L. (2020). High prevalence of ESBL-producing *klebsiella pneumoniae* in clinical samples from central Cote d'Ivoire. *International Journal of Infectious Diseases*, 91, 207-209. <https://doi.org/10.1016/j.ijid.2019.11.024>
- Neill, C. J., Harris, S., Goldstone, R. J., Lau, E. C., Henry, T. B., Yiu, H. H., & Smith, D. G. (2020). Antibacterial activities of Ga(III) against *E. coli* are substantially impacted by Fe(III) uptake systems and Multidrug resistance in combination with oxygen levels. *ACS Infectious Diseases*, 6(11), 2959-2969. <https://doi.org/10.1021/acsinfecdis.0c00425>
- Nejjari, C., El Achhab, Y., Benaouda, A., & Abdelfattah, C. (2022). Antimicrobial resistance among GLASS pathogens in Morocco: An epidemiological scoping review. *BMC Infectious Diseases*, 22(1). <https://doi.org/10.1186/s12879-022-07412-4>
- Ogunshe, A. A. (2019). Assessing food safety implications of multi antibiotic resistant fermented-food-Condiment-Environment-Adapted bacteria. *Journal of Advances in Microbiology*, 1-13. <https://doi.org/10.9734/jamb/2019/v15i230084>
- Otto, S. J., Haworth-Brockman, M., Miazga-Rodriguez, M., Wierzbowski, A., & Saxinger, L. M. (2022). Integrated surveillance of antimicrobial resistance and antimicrobial use: Evaluation of the status in Canada (2014–2019). *Canadian Journal of Public Health*, 113(1), 11-22. <https://doi.org/10.17269/s41997-021-00600-w>
- Ouarti, B., Laroche, M., Righi, S., Meguini, M. N., Benakhla, A., Raoult, D., & Parola, P. (2020). Development of MALDI-TOF mass spectrometry for the identification of lice isolated from farm animals. *Parasite*, 27, 28. <https://doi.org/10.1051/parasite/2020026>
- Pacífico, C., Hilbert, M., Sofka, D., Dinhol, N., Pap, I., Aspöck, C., & Hilbert, F. (2019). Characterization of bacteria and inducible phages in an intensive care unit. *Journal of Clinical Medicine*, 8(9), 1433. <https://doi.org/10.3390/jcm8091433>
- Rajendran, N. B., Mutters, N., Marasca, G., Conti, M., Sifakis, F., Vuong, C., Voss, A., Baño, J., & Tacconelli, E. (2020). Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. *Clinical Microbiology and Infection*, 26(7), 943.e1-943.e6. <https://doi.org/10.1016/j.cmi.2019.11.020>
- Roth, N., Käsbohrer, A., Mayrhofer, S., Zitz, U., Hofacre, C., & Domig, K. J. (2019). The application of antibiotics in broiler production and the resulting antibiotic resistance in *escherichia coli*: A global overview. *Poultry Science*, 98(4), 1791-1804. <https://doi.org/10.3382/ps/pey539>
- Saha, D., & Mukherjee, R. (2019). Ameliorating the antimicrobial resistance crisis: Phage therapy. *IUBMB Life*, 71(7), 781-790. <https://doi.org/10.1002/iub.2010>
- Samaranayake, W. A., Dempsey, S., Howard-Jones, A. R., Outhred, A. C., & Kesson, A. M. (2020). Rapid direct identification of positive paediatric blood cultures by MALDI-TOF MS technology and its clinical impact in the paediatric hospital setting. *BMC Research Notes*, 13(1). <https://doi.org/10.1186/s13104-019-4861-4>
- Schuch, R., Pelzek, A. J., Nelson, D. C., & Fischetti, V. A. (2019). The PlyB Endolysin of bacteriophage vB_BanS_Bcp1 exhibits broad-spectrum bactericidal activity against *Bacillus cereus Sensu Lato* isolates. *Applied and Environmental Microbiology*, 85(9). <https://doi.org/10.1128/aem.00003-19>
- Sisakhtpour, B., Mirzaei, A., Karbasizadeh, V., Hosseini, N., Shabani, M., & Moghim, S. (2022). The characteristic and potential therapeutic effect of isolated multidrug-resistant

- Acinetobacter baumannii* lytic phage. *Annals of Clinical Microbiology and Antimicrobials*, 21(1). <https://doi.org/10.1186/s12941-022-00492-9>
- Sridharan, K., Hasan, H., Al Jufairi, M., Al Daylami, A., Abdul Azeez Pasha, S., & Al Ansari, E. (2021). Drug utilisation in adult, paediatric and neonatal intensive care units, with an emphasis on systemic antimicrobials. *Anaesthesiology Intensive Therapy*, 53(1), 18-24. <https://doi.org/10.5114/ait.2021.103628>
- Sukri, A., Lopes, B. S., & Hanafiah, A. (2021). The emergence of multidrug-resistant *Helicobacter pylori* in Southeast Asia: A systematic review on the trends and intervention strategies using antimicrobial peptides. *Antibiotics*, 10(9), 1061. <https://doi.org/10.3390/antibiotics10091061>
- Surányi, B. B., Zwirzitz, B., Mohácsi-Farkas, C., Engelhardt, T., & Domig, K. J. (2023). Comparing the efficacy of MALDI-TOF MS and sequencing-based identification techniques (Sanger and NGS) to monitor the microbial community of irrigation water. *Microorganisms*, 11(2), 287. <https://doi.org/10.3390/microorganisms11020287>
- Ticcioni, A., Piscitello, K., Bjornstad, M., Hensley, K., Davis, J., Drobac, A., & Canepa, J. (2021). Stepwise development and yearlong assessment of a pharmacist-driven molecular rapid diagnostic test result service for bloodstream infections. *INNOVATIONS in pharmacy*, 12(2), 7. <https://doi.org/10.24926/iip.v12i2.3720>
- Tuat, C. V., Hue, P. T., Loan, N. T., Thuy, N. T., Hue, L. T., Giang, V. N., Erickson, V. I., & Padungtod, P. (2021). Antimicrobial resistance pilot surveillance of pigs and chickens in Vietnam, 2017–2019. *Frontiers in Veterinary Science*, 8. <https://doi.org/10.3389/fvets.2021.618497>
- Turner, P., Fox-Lewis, A., Shrestha, P., Dance, D. A., Wangrangsimakul, T., Cusack, T., Ling, C. L., Hopkins, J., Roberts, T., Limmathurotsakul, D., Cooper, B. S., Dunachie, S., Moore, C. E., Dolecek, C., Van Doorn, H. R., Guerin, P. J., Day, N. P., & Ashley, E. A. (2019). Microbiology investigation criteria for reporting objectively (MICRO): A framework for the reporting and interpretation of clinical microbiology data. *BMC Medicine*, 17(1). <https://doi.org/10.1186/s12916-019-1301-1>
- Ukuhor, H. O. (2021). The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics. *Journal of Infection and Public Health*, 14(1), 53-60. <https://doi.org/10.1016/j.jiph.2020.10.018>
- Urakami, S., & Hinou, H. (2024). MALDI glycotyping of O-antigens from a single colony of Gram-negative bacteria. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-62729-1>
- Vijay, S., Bansal, N., Rao, B. K., Veeraraghavan, B., Rodrigues, C., Wattal, C., Goyal, J. P., Tadepalli, K., Mathur, P., Venkateswaran, R., Venkatasubramanian, R., Khadanga, S., Bhattacharya, S., Mukherjee, S., Baveja, S., Sistla, S., Panda, S., & Walia, K. (2021). Secondary infections in hospitalized COVID-19 patients: Indian experience. *Infection and Drug Resistance*, 14, 1893-1903. <https://doi.org/10.2147/idr.s299774>
- Wang, W., Chen, J., Shao, X., Huang, P., Zha, J., & Ye, Y. (2021). Occurrence and antimicrobial resistance of *Salmonella* isolated from retail meats in Anhui, China. *Food Science & Nutrition*, 9(9), 4701-4710. <https://doi.org/10.1002/fsn3.2266>
- Weis, C., Horn, M., Rieck, B., Cuénod, A., Egli, A., & Borgwardt, K. (2020). Topological and kernel-based microbial phenotype prediction from MALDI-TOF mass spectra. *Bioinformatics*, 36(Supplement_1), i30-i38. <https://doi.org/10.1093/bioinformatics/btaa429>
- Yalew, S. T. (2020). Review on antibiotic resistance: Resistance mechanisms, methods of detection and its controlling strategies. *Biomedical Journal of Scientific & Technical Research*, 24(5). <https://doi.org/10.26717/bjstr.2020.24.004121>
- Yang, J. H., Wright, S. N., Hamblin, M., McCloskey, D., Alcantar, M. A., Schrübbers, L., Lopatkin, A. J., Satish, S., Nili, A., Palsson, B. O., Walker, G. C., & Collins, J. J. (2019). A white-box machine learning approach for revealing antibiotic mechanisms of action. *Cell*, 177(6), 1649-1661.e9. <https://doi.org/10.1016/j.cell.2019.04.016>
- Zingg, W., Park, B. J., Storr, J., Ahmad, R., Tarrant, C., Castro-Sanchez, E., Perencevich, E., Widmer, A., Krause, K., Kilpatrick, C., Tomczyk, S., Allegranzi, B., Cardo, D., & Pittet, D. (2019). Technology for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva IPC-think tank (Part 2). *Antimicrobial Resistance & Infection*

Control, 8(1). <https://doi.org/10.1186/s13756-019-0538-y>

Zingg, W., Storr, J., Park, B. J., Jernigan, J. A., Harbarth, S., Grayson, M. L., Tacconelli, E., Allegranzi, B., Cardo, D., & Pittet, D. (2019).

Broadening the infection prevention and control network globally; 2017 Geneva IPC-think tank (Part 3). *Antimicrobial Resistance & Infection Control*, 8(1). <https://doi.org/10.1186/s13756-019-0528-0>